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Intravesical Bacillus CalmetteeGuerin (BCG) is usually a well-tolerated treatment for urethelial carci-
noma of the bladder. A 60-year-old male endured multiple erythematous white-scaled maculopapules
over his trunk, back, and four extremities after 2 months of the 6-weekly intravesical instillation of BCG.
Skin biopsy revealed parakeratotic hyperkeratosis, intracorneal neutrophilic Munro’s abscess, and
acanthosis. Guttate psoriasis was diagnosed, and he was treated successfully with topical steroid and
narrow band UV-B phototherapy. We present the ﬁrst Asian case of guttate psoriasis associated with
intravesical BCG immunotherapy and review the literatures.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Several cutaneous complications have been reported with the use
of intravesical Bacillus CalmetteeGuerin (BCG) immunotherapy,
the mainstay treatment for superﬁcial bladder cancer. These
complications have included granulomatous lesions of the penis,
painful ulcers and papules, and inguinal lymphadenopathy. Here,
we describe a case with new-onset guttate psoriasis after the
completion of one course of intravesical BCG immunotherapy.
Case report
After diagnosis with high-grade urothelial carcinoma of the
bladder, clinical stage T1N0M0, a 60-year-old male underwent
intravesical BCG immunotherapy in the form of 6-weekly intra-
vesical instillations of BCG. Two months after the sixth BCG instil-
lation, multiple skin lesions appeared on the patient’s trunk, back,
and four extremities. The patient had no history of psoriasis or
other systemic diseases, and no signs of acute upper respiratory
tract infection had been noted before the onset of the skin lesions.
Furthermore, no family history of psoriasis was traced.
Physical examination revealed numerous scattered asymptom-
atic erythematous white-scaled papules and plaques involving theh.D., No. 325, Sec. 2, Cheng-
C. Tel.: þ886 2 87927180;
g).
iwanese Dermatological Associatiotrunk, back, and four extremities as well as Auspitz’s sign, but no
pitted nails or dermatological complications of the scalp, face, or
palmoplantar regions (Figure 1A). The results of tissue biopsy from
the medial aspect of the right forearm revealed the presence of
parakeratotic hyperkeratosis, acanthosis (Figure 2A), and intra-
corneal neutrophilic Munro’s abscess (Figure 2B). Observation of
immunohistochemical staining with activated phospho-Stat-3
(Tyr705; 1:1000) and psoriasin (S100A7; 1:750) revealed the
concentration of the former in the nuclei of the keratinocytes
(Figure 3A) and of the latter in the epidermis of the lesions
(Figure 3B). Based on these clinical and pathological ﬁndings, the
patient was diagnosed with guttate psoriasis.
The patient was treated with 18 applications of systemic
narrow-band UV-B phototherapy (300e1200 mJ) and twice-daily
application of 0.1% diﬂucortolone valerate cream on the lesions.
This treatment, which relieved his symptoms, resulted in the
development of Woronoff’s rings in the normal skin adjacent to the
psoriatic macules (Figure 1B). Three weeks after beginning
dermatological therapy, the patient resumed BCG instillation
immunotherapy to treat his bladder cancer. As anticipated, the
extent of his guttate psoriasis worsened with the resumption of
BCG instillation immunotherapy.
Discussion
Vaccinationwith BCG, a live attenuatedMycobacterium bovis vaccine
used to stimulate the immune system and prevent severe forms
of infection caused by mycobacterium tuberculosis, is practiced
on a national scale in Taiwan. However, several dermatologicaln. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (A) Multiple erythematous white-scaled maculopapules involving the trunk, back, and four extremities. (B) After narrow band UV-B and topical steroid treatment,
Woronoff’s rings developed in the normal skin adjacent to psoriatic macules.
Figure 2 Histiological features of the lesion. (A) The macule located on the medial side of forearm reveals hyperkeratotic acanthosis with a dermal cellular inﬁltration [hematoxylin
and eosin (H&E), 40]. (B) There are multiple intracorneal neutrophilic Munro’s abscess (H&E, 400).
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severity of the complications depending on the immunity of the
host. Skin complications that have been reported in immuno-
competent hosts include juvenile sarcoidosis over the dorsum of
the hands and feet,1 keloid and delayed tuberculoid granuloma
formation on the BCG vaccination site,2 and granulomatous
inﬂammation of vaccination site in patients with Kawasaki’s
disease.3 In 1955, Raaschou-Nielsen4 reported the ﬁrst case of
psoriasis following BCG vaccination that appears in the literature.Figure 3 Immunohistochemical staining showing (A) Phospho-Stat-3 [1:1000; Phospho-Sta
the nuclei of the keratiocytes (400). (B) Psoraisin (S100A7; 1:750; Abcam, Cambridge, MAIn 2004, Koca et al5 reported the successful treatment of a case in
the form of guttate psoriasis-like lesions on a 7-year-old boy 1
week after BCG vaccination with 3 weeks of topical corticosteroid
therapy.
In addition to serving a means of vaccination, intravesical BCG
immunotherapy is regarded as a standard and well-tolerated
means of treating superﬁcial bladder cancer. The mechanism
underlying the therapeutic effect of BCG instillation is induction of
inﬂammation and stimulation of helper and killer T lymphocytes,t-3 (Tyr705) antibody; Cell Signaling Technology Inc., Beverly, MA, USA] is expressed in
, USA) is expressed in the whole layer of the epidermis (400).
Table 1 Clinical features of cases with psoriasis associated with intravesical Bacillus CalmetteeGuerin (BCG) published in the literature.
No. Sex/age
and race
Location/morphology Bladder cancer
(grading)
Past history
of psoriasis
Additional ﬁndings Treatment Reference
1 M/52
NA
Plaques of psoriasis on the
elbows
Grade III Yes Fever, oral ulcer, synovitis in
both wrists, MCP joints and
right knee, dactylitis in the
second toe of the left foot, and
the forth toe of the right foot
NSAIDs and steroid inﬁltrations Queiro
et al9
2 M/76
Caucasian
White-scaled plaques in the
extensor extremities and
scalp, nummular guttate
macules on the trunk
NA No Mild arthralgia involving
hand and wrist joints with
swelling if multiple digits
Etanercept 50 mg twice weekly. A
twice-daily application of
halobetasol ointment to the body,
betamethasone valerate solution to
the scalp, and calcipotriene solution
to the scalp and body plaques
Dudelzak
et al10
3 M/60
Taiwanese
Multiple guttate white-
scaled papules/plaques
over the trunk, back, and
four extremities
High grade No No fever or arthralgia was
noted; relapsed after
following BCG instillation
Narrow-band UV-B phototherapy.
A twice-daily application of
diﬂucortolone valerate cream
Present
case
MCP¼metacarpophalangeal; NA¼ not available; NSAIDs¼ non-steroidal anti-inﬂammatory drugs.
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tumor cells. The complications of BCG immunotherapy range from
irritative lower urinary tract symptoms to sepsis. The side effects
include granulomatous prostatitis, epididymo-orchitis, hepatitis,
and pneumonitis.6 Several cutaneous side effects have also been
reported, with two case reports describing the development of
granulomatous lesions of the penis accompanied with penile
swelling and edema, painful ulcers and papules, and inguinal
lymphadenopathy after six instillations of BCG treatment.7,8 The
mycobacterial stain and cultures of both cases were negative, but
both were treated successfully with antitubercular regimens.
The other rare cutaneous complication that has been reported is
psoriasis, of which only two cases have been described in the
literature (Table 1).9,10 In 1995, Queiro et al9 ﬁrst reported the
exacerbation of psoriatic polyarthropathy with dactylitis in a 52-
year-old man with psoriasis following BCG immunotherapy. After
suspension of BCG treatment, the patient was successfully treated
with non-steroidal anti-inﬂammatory drugs and steroid inﬁltra-
tions. In 2008, Dudelzak et al10 reported the ﬁrst case of new-onset
psoriasis and psoriatic arthritis after instillation of BCG. With
treatment of etanercept and topical steroids, the patient’s symp-
toms signiﬁcantly improved. In the case of new-onset guttate
psoriasis following intravesical BCG immunotherapy reported here,
the patient was successfully treated with topical steroids and
narrow-band UV-B phototherapy but experienced relapse after
resumption of BCG instillation.
The relationship between guttate psoriasis and intravesical BCG
instillation remains uncertain, with the activated immune system
hypothesized to play an important role in psoriasis pathogenesis.
The mechanism by which intravesical BCG treats bladder cancer is
a complex process that is also not completely understood. Based on
the knowledge that BCG particles are internalized and processed by
antigen-presenting cells and tumor cells, it is hypothesized that
BCG antigens are present on the cell surface where, via major
histocompatibility complex molecules, they activate T lympho-
cytes.11 Such activation may induce inﬂammation, which in turn
induces the production of several cytokines, including interferon-
gamma, tumor necrosis factor-beta, and interleukin (IL)-1, 2, 5, 6,
8, 10, 12, and 18.11,12 IL-6 production and BCG internalization
relate to the differentiation of the tumor cells.13 In contrast to the
well-differentiated transitional cell carcinoma (TCC) cells, the
poorly differentiated cell lines have been found to allow them to
internalize BCG and up-regulate IL-6 synthesis. This ﬁnding
correlates with the clinical observation of a lower recurrence rate
of high-grade TCC with BCG instillation compared to low-grade
TCC.14,15IL-6 has been found to induce not only differentiation of Th17
cells but also production of IL-22 from naïve T cells.16,17 In addition
to the ﬁnding that IL-22 induces the proliferation of keratinocytes
and activates Stat-3 with nuclear localization and production of
psoriasin (S100A7),18,19 both Th17 and IL-22 play important roles in
the pathogenesis of psoriasis. In the present case, activated
phospho-Stat-3 was found in the nuclei of keratinocytes in the skin
lesion (Figure 3A), and psoriasin was strongly stained in the entire
epidermis of lesional skin (Figure 3B). Both ﬁndings may suggest an
activation of IL-22 in the psoriatic plaque of our patient.
In conclusion, we report a case of guttate psoriasis after the
intravesical BCG instillation for the treatment of urothelial carci-
noma of the bladder. Hewas treated successfully with narrow-band
UV-B phototherapy and topical corticosteroids. Nowadays, use of
intravesical BCG immunotherapy for the superﬁcial bladder cancer
is quite common. Dermatologists should be aware of this potential
cutaneous complication of BCG therapy.References
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